Summary by Moomoo AI
EyePoint Pharmaceuticals announced the dosing of first patient in LUCIA trial, its second global Phase 3 study of DURAVYU (formerly EYP-1901) for wet age-related macular degeneration treatment. The company is running two simultaneous Phase 3 trials - LUCIA and LUGANO, with over 240 global sites committed and topline data anticipated in 2026.DURAVYU, a sustained delivery therapy using vorolanib and proprietary Durasert E technology, aims to reduce treatment burden in wet AMD patients. The Phase 3 program includes both treatment-naive and experienced patients, with DURAVYU administered every six months. The trials will evaluate efficacy through best corrected visual acuity changes and safety across approximately 400 patients per trial.The Phase 2 DAVIO 2 trial demonstrated promising results with approximately 88% treatment burden reduction at eight months and over 80% of patients requiring one or no supplemental anti-VEGF injections. The company is also conducting a Phase 2 VERONA trial for diabetic macular edema, with full topline data expected in Q1 2025.
